Option chain shows key data for New Century Logistics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for New Century Logistics.

New Century Logistics (NASDAQ:NCEW) Stock, Option Chain

New Century Logistics

New Century Logistics (BVI) Ltd is a well-established freight forwarding service provider based in Hong Kong. The company provides air and ocean export and import freight forwarding services ranging from the sale of cargo space, cargo pick up, off-airport air cargo security screening, palletization, preparation of shipping documentation, and arrangement of customs clearance to cargo handling at ports. It provides a full range of logistics services by providing to its customers with a robust international network that strategically supports the movement of its customers' goods. Includes various logistic like New Century Logistics Company Limited, GLF Cargo Services Limited, Win-Tec Transportation Company Limited.

New Century Logistics (BVI) Limited - Ordinary Shares

New Century Logistics (BVI) Ltd

Scotiabank analyst Mario Saric maintains Riocan REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/REI#TSX">REI</a>) with a Sector Perform and raises the price target from C$20.75 to C$21.5.

News

Price Target

Analyst Ratings

TSX:REI

TSX:REI/UN

Scotiabank Maintains Sector Perform on Riocan REIT, Raises Price Target to C$21.5

Financial technology company Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) could highlight its growth across several sectors along with its place in the cryptocurrency ecosystem when the company reports fourth-quarter financial results Thursday <a href="https://www.benzinga.com/quote/XYZ/earnings">after market close.</a>
Earnings Estimates: Analysts expect Block to report fourth-quarter revenue of $6.29 billion, up from $5.77 billion in last year's fourth quarter.
The company missed analyst revenue estimates in the last two straight quarters, but has beaten estimates in eight of the last 10 quarters.
Analysts expect the company to report fourth-quarter earnings per share of 87 cents, up from 45 cents per share in last year's fourth quarter. The company has beaten analyst estimates for earnings per share in three straight quarters and eight of the last 10 quarters overall.
What Analysts Are Saying: The resurgence of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) could be a positive narrative for Block, RBC Capital analyst Daniel Perlin said in a new investor note.
The analyst has an Outperform rating and $110 price target ahead of fourth-quarter earnings.
"Given the resurgence in investor interest in bitcoin and the expectation for regulatory clarity, we believe that XYZ's 4Q24 results will include increased commentary regarding it leaning more into its bitcoin strategy," Perlin said.
The analyst said this could include comments on the company's crypto mining and wallets efforts along with commerce use cases.
"We believe the increased commentary combined with a positive narrative will drive investor interest, who will begin the bake more than just its core Cash App and Square businesses into the stock's valuation."
The analyst highlighted Block's 8,363 reported held bitcoin at the end of the third quarter along with incremental bitcoin purchases that could total around $781 million in holdings at the end of the fourth quarter.
Block's push into bitcoin mining could highlight the company's technological expertise and growth in the cryptocurrency ecosystem, Perlin added.
"The bitcoin narrative has more substance now. While positive for the stock, we don't see bitcoin sales as the reason to buy XYZ. What we do see as a more legitimate reason is the belief that longer-term, Block will leverage its two-sided network and integration with the Lightning Network to be the facilitator of bitcoin's commerce use case."
The analyst said Block will operate in several crypto sectors where there are only a handful of competitors.
The analyst views President Donald Trump's pro-crypto stance as positive for Block. The president has appointed several crypto advocates to notable financial roles in the White House administration.
"We believe that regulatory momentum has no reason to slow, which could lead to a greater level of bitcoin's integration into traditional financial services and commerce."
Bank of America analyst Jason Kupferberg recently named Block as a top Payments pick for 2025. The analyst has a Buy rating and a $115 price target.
Kupferberg said Block has the potential to outperform thanks to a favorable macro backdrop and growth in the company's Square gross payments volume.
The analyst said Block will likely achieve the Rule of 40, or revenue growth and profit margin added together, equaling 40 or more, sooner than anticipated. Kupferberg predicts this could lead to Block being added to the S&amp;P 500.
XYZ Price Action: Block stock is down 1.3% to $82.78 on Thursday versus a 52-week trading range of $55.00 to $99.26. Block stock is up 25% over the last year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43856737/applovin-stock-tumbles-as-short-seller-takes-a-closer-look-at-whats-driving-enormous-gains">AppLovin Stock Tumbles As Short Seller Takes Closer Look At What&#8217;s Driving Enormous Gains</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Tech

$BTC

Block Q4 Earnings Preview: Analyst Says Bitcoin, Trump Factor Could Boost Growth

Scotiabank analyst Orest Wowkodaw maintains Hudbay Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HBM#TSX">HBM</a>) with a Sector Outperform and lowers the price target from C$15.5 to C$14.

TSX:HBM

Scotiabank Maintains Sector Outperform on Hudbay Minerals, Lowers Price Target to C$14

Indivior Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) stock plunged following the company&#8217;s fiscal year 2025 guidance that fell short of Street expectations.
Addiction and mental illnesses-focused Indivior reported fourth-quarter sales of $298 million, up 2% year over year, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the consensus</a> of $259.3 million.
The London-based healthcare firm <a target="_blank" href="https://www.indivior.com/resources/dam/id/1487/Indivior%20Q4%202024%20Financial%20Results%20-%20Final.pdf" rel="noreferrer noopener">reported</a> adjusted EPS of 32 cents, down from 43 a year ago, beating the consensus of 21 cents.
In the fourth quarter, adjusted operating profit remained unchanged at $66 million, while adjusted net income declined 33% year-over-year to $41 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41272212/indivior-cuts-2024-outlook-as-competition-and-market-pressures-weigh-on-sublocade-details" rel="noreferrer noopener">Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details</a>
Sales of Sublocade, its newer long-acting treatment for opioid use disorder, increased 10% year over year to $194 million, and U.S. units dispensed were approximately 161,400, up 13%.
Suboxone Film revenue declined in the fourth quarter due to increased generic competitive activity, resulting in an average share of 15.2% versus 18.4% a year ago.
Sales of Perseris, its schizophrenia drug, fell 25% to $9 million. As previously announced, Perseris&#8217; marketing and promotion have been discontinued.
In February, the FDA informed Indivior that, following acceptance of the proposed label for Sublocade, there were no outstanding items for the company to address, but the final review of the label was delayed.
Guidance: Indivior expects 2025 revenue of $955 million to $1.025 billion, versus a consensus of $1.09 billion, representing a 17% decline.
The company expects adjusted EBIT guidance of $185 million to $225 million. Sublocade sales are expected to reach $725 million to $765 million, down 1% year over year.
The guidance anticipates accelerated erosion in Suboxone sales, reflecting an increased generic competitive activity and the potential impact of a fifth buprenorphine/ naloxone sublingual film generic in the U.S. market.
Indivior is cutting over $100 million in costs, of which approximately $50 million will be reinvested in Sublocade and the opioid use disorder-focused pipeline. Over $50 million will help protect adjusted operating profit.
Price Action: INDV stock is down 16.50% to $9.11 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43849900/airbus-q4-earnings-revenue-surges-8-order-intake-value-declines-and-more" target="_blank" rel="noreferrer noopener">Airbus Q4 Earnings: Revenue Surges 8%, Order Intake Value Declines And More</a></li>
</ul>

Biotech

Earnings

Guidance

Eurozone

Health Care

Movers

Trading Ideas

General

INDV

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Scotiabank analyst Mario Saric maintains CAPREIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CAR#TSX">CAR</a>) with a Sector Outperform and lowers the price target from C$52.25 to C$50.

TSX:CAR

TSX:CAR/UN

Scotiabank Maintains Sector Outperform on CAPREIT, Lowers Price Target to C$50

Wall Street analysts rerated Wix.com Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) after the company reported its <a target="_blank" href="https://www.benzinga.com/25/02/43812289/wix-q4-earnings-beats-estimates-raises-2025-outlook-ai-powered-expansion-and-market-share-gains" rel="noreferrer noopener">fourth-quarter results</a> Wednesday amid an exciting earnings season.
Wix.com reported revenue growth of 14%&nbsp;to $460.46 million, missing the&nbsp;analyst estimate of $461.75 million.&nbsp;Adjusted EPS of $1.93 beat the&nbsp;consensus estimate of $1.59.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43846533/alibaba-q3-earnings-revenue-and-eps-beat-eyes-global-e-commerce-profitability-in-fy25-increase-investments-in-ai" rel="noreferrer noopener">Alibaba Q3 Earnings: Revenue And EPS Beat, Eyes Global E-Commerce Profitability In FY25, Increase Investments In AI</a>
Cantor Fitzgerald analyst Deepak Mathivanan maintained Wix.com with an Overweight and raised the <a target="_blank" href="https://www.benzinga.com/quote/WIX/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$260&nbsp;to&nbsp;$270</a>.
Benchmark analyst Mark Zgutowicz reiterated Wix.com with a Buy and raised the price target from&nbsp;$250&nbsp;to&nbsp;$260.
Needham analyst Bernie McTernan maintained Wix.com with a Buy and raised the price target from&nbsp;$235&nbsp;to&nbsp;$250.
RBC Capital analyst Brad Erickson reiterated an Outperform on Wix.com with a price target of $245.
Cantor Fitzgerald: WIX reported fourth-quarter results with revenue in line and free cash flow above Street estimates by 2% (Visible Alpha).
Mathivanan highlighted Studio adoption reflected by its booking growth, momentum in Self Create supported by the rollout of new AI products—the company&#8217;s AI marketing agent has entered the rollout phase—and premium subscriptions led by pricing initiatives and tougher comp from B2B migrations in 2023.
The analyst noted that the company&#8217;s robust product pipeline in 2025 bodes well for top-line growth. Operating margins also have plenty of runway to expand nicely over the next few quarters. Mathivanan projected first-quarter revenue of $472.1 million and adjusted EPS of $1.30.
Benchmark: WIX&#8217;s first-quarter and fiscal 2025 outlook tempered concerns for difficult pricing-related bookings headwind comparisons starting in mid-first-quarter, as the entirety of the respective fiscal 2025 bookings and revenue miss were attributed to FX headwinds.
Notably, WIX&#8217;s fiscal 2025 free cash flow guidance incorporates adjusted opex as a percent of revenue between 47% and 48%, in line with targets set at its fiscal 2023 Investor Day.
Importantly, WIX has not assumed any revenue generation from new products within fiscal 2025 guidance, presenting a potential average revenue per subscription (ARPS) catalyst in the second half across both Self-Creators and Partners.
An underappreciated aspect of the free cash flow margin story remains the sustainable and eventually accretive revenue mix shift toward Partners. Notably, partners&#8217; revenue exhibits lower S&amp;M sensitivities than Self-Creator today, allowing rationalize Partners&#8217; (eventual) accretion potential and emerging automation-based efficiencies.
Regarding WIX&#8217;s top-of-funnel momentum, Zgutowicz is impressed with 75% of the 2M Studio account net adds since launch being net new Partner clients to WIX. Zgutowicz anticipated potential top-of-funnel Partner (Agency) deceleration, given difficult comparisons.
However, the analyst expects Studio to drive accelerative ARPS growth in the second half as Bookings materialize into revenue. Zgutowicz anticipates its new Partner subscribers will deliberately shift portions of workflow to Studio, providing a sustainable ARPS benefit over the medium-to-long term, with pricing power and product innovation at its disposal. Zgutowicz projected first-quarter revenue of $472 million.
Needham: WIX continues to be one of the best product-driven growth stories in McTernan&#8217;s coverage. However, the company&#8217;s reported fiscal 2025 growth is being impacted by FX and compared against a price increase from the prior year. WIX studio is driving many new developers/agencies to the platform, which should be of lasting benefit. 
On Self Creator, WIX is launching new products this year, which could re-accelerate revenue to double-digits, representing an upside to the analyst&#8217;s estimates. McTernan projected first-quarter revenue of $471 million and adjusted EPS of $1.73.
RBC Capital: WIX&#8217;s fourth-quarter print was somewhat mixed, with the main intrigue being the fiscal bookings guide below Street (in-line FX neutral), where expected second-half bookings acceleration implies the year will be more back-end weighted than Street forecasts.
Erickson rerated despite the stock&#8217;s firm run on further new product cycle optimism and rising potential to become a more fully-formed compounder/capital return story. Erickson projected first-quarter revenue of $471.2 million.
Price Action: WIX stock traded lower by 4.82% at $206.54 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43853508/grab-q4-on-demand-incentives-grow-due-to-competition-issues-cautious-fy25-outlook-despite-strong-gmv-and-user-growth" target="_blank" rel="noreferrer noopener">Grab Q4 On-Demand Incentives Grow Due To Competition, Issues Cautious FY25 Outlook Despite Strong GMV And User Growth</a></li>
</ul>
Image via Shutterstock.

Equities

Reiteration

Wix Is One Of The Best Product-Driven Growth Stories, Analyst Says

Scotiabank analyst Meny Grauman maintains Toronto-Dominion Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) with a Sector Perform and lowers the price target from C$83 to C$82.

TSX:TD

Scotiabank Maintains Sector Perform on Toronto-Dominion Bank, Lowers Price Target to C$82

Barstool Sports founder Dave Portnoy, known for his outspoken commentary, is calling for a sweeping &#8220;clean up&#8221; of the cryptocurrency space as the Stool Prisondente (CRYPTO: JAILSTOOL), is <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43643442/dave-portnoy-holds-millions-in-bitcoin-and-xrp-but-heres-why-he-concluded-his-heart-is-too">plummeting in value.</a>
In a post on X Thursday, Portnoy <a href="https://x.com/stoolpresidente/status/1892594369733206090">wrote</a>, "So manny scammers and liars out there. Let's clean this space up! Take out the trash. Together we can win. This is when it pays to be the cleanest man in crypto."
His remarks come just days after Jailstool's price dropped from 21 cents to 1 cent, wiping out millions of <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43636904/anthony-scaramucci-warns-meme-coins-create-market-contagion-fuel-bitcoin-skepticism">dollars of investor funds</a>, according to data from Dexscreener.
&#8220;Can we arrest the crybabies who are told not to risk more than they can lose and that Memecoins are a risk and then cry foul too?&#8221; he further said, in an apparent dig at retail investors, who lost funds investing in the meme coin.
While Portnoy insists he remains committed to the project, his role in its promotion has divided the crypto community.
<h3 class="wp-block-heading">Portnoy's Role In The Jailstool Crash</h3>
Portnoy claimed he had initially invested hundreds of thousands of dollars into Jailstool and publicly declared his support for the token. 
Even as prices tumbled, he insisted he was putting in more of his own money to prevent losses for other investors.
"The fact I'm still putting my own money into #Jailstool cause I don't want people losing money shows that my heart is too big for this stupid space," Portnoy posted on X.
Despite his claims of loyalty to the project, Jailstool's sharp decline has fueled accusations that his marketing efforts failed, leaving retail investors at a disadvantage.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43857831/sec-scales-back-crypto-enforcement-expands-focus-to-cyber-fraud">SEC Scales Back Crypto Enforcement, Expands Focus To Cyber Fraud</a>
<h3 class="wp-block-heading">Market Reaction And Crypto Community Divisions</h3>
The crypto community remains split on Portnoy's role. 
Some believe he is genuinely backing the coin, while others argue his involvement has caused more harm than good.
Crypto analyst Stats pointed out that Jailstool has nearly returned to its pre-promotion price, raising concerns about the effectiveness of Portnoy's influence.
"His marketing plays didn't work out. People lost real money (which is 100% their own fault). But I think his credibility in this space is pretty ruined," Stats wrote.
Others, such as Kaleo, speculated that Portnoy may keep investing in Jailstool to salvage its price. They suggested that if he faces further losses, he may turn against meme coins altogether.
<h3 class="wp-block-heading">What's Next For Portnoy And Jailstool?</h3>
While Portnoy maintains that he could have cashed out for millions but chose not to, questions remain about his long-term involvement in crypto. 
His call to "clean up the space" has been met with skepticism, as many point to Jailstool's crash as an example of why stronger oversight is needed.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43855374/studying-bitcoin-will-strengthen-us-czech-central-bank-governor-says">Studying Bitcoin Will Strengthen Us, Czech Central Bank Governor Says</a></li>
</ul>
Image: Shutterstock

Dave Portnoy Calls For A 'Crypto Cleanup,' But Here's What Could Make That Tricky

Scotiabank analyst Meny Grauman maintains Royal Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RY#TSX">RY</a>) with a Sector Outperform and lowers the price target from C$197 to C$191.

TSX:RY

Scotiabank Maintains Sector Outperform on Royal Bank of Canada, Lowers Price Target to C$191

Scotiabank analyst Meny Grauman maintains National Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NA#TSX">NA</a>) with a Sector Perform and lowers the price target from C$154 to C$125.

TSX:NA

Scotiabank Maintains Sector Perform on National Bank of Canada, Lowers Price Target to C$125

EYPT

Traders Circulate Unconfirmed Report On Social Media That Eyepoint Pharmaceuticals Received National Medical Products Administration Approval Of Dexycu In China To Treat Post-Operative Inflammation Following Ocular Surgery

Scotiabank analyst Meny Grauman maintains Laurentian Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LB#TSX">LB</a>) with a Sector Perform and lowers the price target from C$33 to C$28.

TSX:LB

Scotiabank Maintains Sector Perform on Laurentian Bank of Canada, Lowers Price Target to C$28

Options

Markets

Schlumberger Option Alert: Feb 28 $44 Calls Sweep (55) near the Ask: 2075 @ $0.29 vs 741 OI; Earnings 4/21 Before Open [est] Ref=$42.865

13 analysts have expressed a variety of opinions on Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Block, revealing an average target of $104.38, a high estimate of $120.00, and a low estimate of $65.00. This current average reflects an increase of 14.7% from the previous average price target of $91.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740078110_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Block among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Andrew Schmidt</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vasundhara Govil</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>John Davis</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Vasundhara Govil</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$105.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Harshita Rawat</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Block. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Block compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Block's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Block's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XYZ/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Block analyst ratings.</a>
<h2>Discovering Block: A Closer Look</h2>
Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2023, Square's payment volume was a little over $200 million.
<h3>Block: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Block displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 6.38%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Block's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 4.75%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.45%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Block's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.77%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Block's debt-to-equity ratio is below the industry average. With a ratio of 0.37, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Block's Future

Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $47.43, a high estimate of $54.00, and a low estimate of $42.00. Observing a downward trend, the current average is 2.21% lower than the prior average price target of $48.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1740078102_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Devon Energy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$52.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Bob Brackett</td>
<td>Bernstein</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$42.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Devon Energy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Devon Energy compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Devon Energy's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Devon Energy's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DVN/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Devon Energy analyst ratings.</a>
<h2>About Devon Energy</h2>
Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. At the end of 2023, Devon reported net proved reserves of 1.8 billion barrels of oil equivalent. Net production averaged roughly 658,000 barrels of oil equivalent per day in 2023 at a ratio of 73% oil and natural gas liquids and 27% natural gas.
<h3>Devon Energy's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Devon Energy displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 9.42%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Devon Energy's net margin excels beyond industry benchmarks, reaching 14.51%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Devon Energy's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Devon Energy's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.1% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.63, Devon Energy adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Devon Energy Through The Eyes Of 14 Analysts

Bittensor's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TAO</a>) recent surge comes as an announcement that Coinbase will soon support Bittensor generates <a href="https://www.benzinga.com/money/what-is-bittensor-tao">buzz on social media.</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Bittensor (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TAO</a>)</td>
<td>&nbsp;$454.58</td>
<td>$3.81 billion</td>
<td>+9.5%&nbsp;</td>
<td>+20.7%&nbsp;</td>
</tr>
<tr>
<td>NEAR Protocol (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/near/usd">NEAR</a>)</td>
<td>&nbsp;$3.41</td>
<td>$4.04 billion</td>
<td>+8.9%</td>
<td>+2.9%&nbsp;</td>
</tr>
<tr>
<td>Internet Computer (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ICP</a>)</td>
<td>&nbsp;$7.09</td>
<td>$3.4 billion</td>
<td>+3.4%&nbsp;</td>
<td>+0.6%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Industry expert Quinten Francois predicts TAO to reach $640 and not even a "rugpulling president can do anything about that."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24TAO&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TAO</a> is going back to $640 and not even a rugpulling president can do anything about that <a href="https://t.co/3WLdWWDTHB">pic.twitter.com/3WLdWWDTHB</a>
&mdash; Quinten &#x7C; 048.eth (@QuintenFrancois) <a href="https://twitter.com/QuintenFrancois/status/1892506026156470383?ref_src=twsrc%5Etfw">February 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto trader McKenna <a href="https://x.com/Crypto_McKenna/status/1892523117685391418">notes</a> that TAO has broken its bearish structure, transitioning to dynamic TAO—which helps reduce supply-side inflation. While subnets are initially inflationary, they could drive long-term value and fuel the next AI speculation cycle.
Bluntz Capital <a href="https://x.com/Bluntz_Capital/status/1892452875798007918">remains</a> long on TAO highlighting a clear 5-wave rally followed by an ABC correction on higher timeframes and a confirmed downtrend break, signaling renewed bullish momentum.
Statistics: Crypto analyst Miles Deutscher emphasizes TAO's ecosystem growth with subnet tokens. While participation requires a learning curve, early adopters could see significant benefits.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The <a href="https://twitter.com/search?q=%24TAO&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TAO</a> ecosystem has been heating up since the launch of Subnet tokens. &#x1f525; There is a learning curve to get involved with it, but that kind of friction creates an opportunity for people who put in the extra work to be early and reap the rewards. <a href="https://t.co/U4KSJUzndj">pic.twitter.com/U4KSJUzndj</a>
&mdash; Miles Deutscher (@milesdeutscher) <a href="https://twitter.com/milesdeutscher/status/1892516053613514957?ref_src=twsrc%5Etfw">February 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Community News: Coinbase Assets <a href="https://x.com/CoinbaseAssets/status/1892256329592369224">announced</a> that it will list Bittensor (TAO) on the Bittensor network. Deposits will be available on Coinbase &amp; CoinbaseExch in supported regions. Trading is scheduled to start today, pending liquidity.
Posty, a crypto trader, <a href="https://x.com/PostyXBT/status/1892561090044629044">called</a> the Coinbase listing a game-changer, stating that TAO is positioned to become the leading AI crypto project. Unlike many AI tokens already on Coinbase, Bittensor performed strongly even before its listing, showcasing its organic demand. 
Read Next:&nbsp;
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43792319/record-breaking-token-creation-in-january-raises-concerns-over-altcoin-liquidity-market-quality">Record-Breaking Token Creation In January Raises Concerns Over Altcoin Liquidity, Market Quality</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

$ICP

$NEAR

$TAO

Bittensor Outshines Dogecoin, Shiba Inu Behind With 18% Gains In 7 Days: How High Can TAO Go?

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Trupanion, revealing an average target of $48.5, a high estimate of $57.00, and a low estimate of $41.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.0%. 
<img src="https://www.benzinga.com/files/images/story/2025/1740078093_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Trupanion. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Trupanion. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Trupanion compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Trupanion's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Trupanion's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TRUP/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Trupanion analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Trupanion</h2>
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
<h3>Trupanion: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Trupanion's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.55% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.44%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Trupanion's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.46%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Trupanion's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.18%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Trupanion's debt-to-equity ratio stands notably higher than the industry average, reaching 0.4. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TRUP

Assessing Trupanion: Insights From 4 Financial Analysts

14 analysts have expressed a variety of opinions on Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.07, a high estimate of $154.00, and a low estimate of $105.00. Marking an increase of 9.54%, the current average surpasses the previous average price target of $116.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740078086_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Shift4 Payments. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rayna Kumar</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$125.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Nate Svensson</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$120.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$121.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$109.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Jason Kupferberg</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Shift4 Payments. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Shift4 Payments compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Shift4 Payments's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Shift4 Payments's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FOUR/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Shift4 Payments analyst ratings.</a>
<h2>Get to Know Shift4 Payments Better</h2>
Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.
<h3>Shift4 Payments: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Shift4 Payments's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 34.62%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 5.92%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 7.11%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.26%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Shift4 Payments's debt-to-equity ratio stands notably higher than the industry average, reaching 3.54. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FOUR

Where Shift4 Payments Stands With Analysts

Throughout the last three months, 9 analysts have evaluated Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Halozyme Therapeutics and provided 12-month price targets. The average target is $66.78, accompanied by a high estimate of $75.00 and a low estimate of $53.00. Holding firm without variation, the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1740078076_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Halozyme Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$72.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$53.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Halozyme Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Halozyme Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Halozyme Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Halozyme Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HALO/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Halozyme Therapeutics analyst ratings.</a>
<h2>About Halozyme Therapeutics</h2>
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
<h3>Halozyme Therapeutics: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Halozyme Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 29.55% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 45.98%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Halozyme Therapeutics's ROE excels beyond industry benchmarks, reaching 33.56%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Halozyme Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of 6.55%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Halozyme Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 4.14. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HALO

Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts

Across the recent three months, 8 analysts have shared their insights on Amplitude (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPL#NASDAQ">AMPL</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.75, with a high estimate of $17.00 and a low estimate of $11.00. This current average has increased by 23.53% from the previous average price target of $11.94. 
<img src="https://www.benzinga.com/files/images/story/2025/1740078065_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Amplitude. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Koji Ikeda</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$12.50</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Amplitude. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amplitude compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Amplitude's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Amplitude's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMPL/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Amplitude analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Amplitude's Background</h2>
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
<h3>Amplitude's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Amplitude's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.48%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Amplitude's net margin is impressive, surpassing industry averages. With a net margin of -22.41%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Amplitude's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -5.84%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Amplitude's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -3.78%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.02, Amplitude adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPL

The Analyst Verdict: Amplitude In The Eyes Of 8 Experts

Press Releases

New Century, consulted by ATIF, successfully listed on Nasdaq

ATIF

NCEW

ZBAI

Air T

Air Transport Services Group, Inc - Common Stock

Air Transport Services Gr

Addentax Group

BEST Inc. American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

BEST

C.H. Robinson Worldwide, Inc. - Common Stock

C.H. Robinson Worldwide

Callan Jmb

Freightos

Expeditors International of Washington, Inc. Common Stock

Expeditors Intl

FedEx

BingEx Limited - American Depositary Shares

BingEx

Freight Technologies, Inc. - Ordinary Shares

Freight Technologies

Forward Air

Globavend Holdings

GXO Logistics

Hong Kong Pharma Digital Technology Holdings Limited - Ordinary shares

Hong Kong Pharma Digital

Hub Group

Jayud Global Logistics Limited - Class A Ordinary Shares

Jayud Global Logistics

PS International Group Ltd. - Ordinary Shares

PS International Group

Radiant Logistics

Shengfeng Development Limited - Class A Ordinary Shares

Shengfeng Development

United Parcel Service

ZTO Express (Cayman) Inc. American Depositary Shares, each representing one Class A ordinary share.

Comments

New Century Logistics

New Century Logistics (NCEW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga